이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Xbrane Biopharma 관리

관리 기준 확인 4/4

Xbrane Biopharma's CEO는 Martin Amark, Jan2015 에 임명되었습니다 의 임기는 9.42 년입니다. 총 연간 보상은 SEK 3.36M, 77% 로 구성됩니다. 77% 급여 및 23% 보너스(회사 주식 및 옵션 포함). 는 SEK 54.44K 가치에 해당하는 회사 주식의 0.012% 직접 소유합니다. 54.44K. 경영진과 이사회의 평균 재임 기간은 각각 9.4 년과 5.1 년입니다.

주요 정보

Martin Amark

최고 경영자

SEK 3.4m

총 보상

CEO 급여 비율	77.0%
CEO 임기	9.5yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	9.5yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12

What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?

Dec 16

Insider Buying: The Xbrane Biopharma AB (publ) (STO:XBRANE) Head of Manufacturing & Supply Chain Just Bought 50% More Shares

Nov 20

CEO 보상 분석

Martin Amark 의 보수는 Xbrane Biopharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-SEK 361m
Dec 31 2023	SEK 3m	SEK 3m	-SEK 322m
Sep 30 2023	n/a	n/a	-SEK 285m
Jun 30 2023	n/a	n/a	-SEK 246m
Mar 31 2023	n/a	n/a	-SEK 189m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 169m
Sep 30 2022	n/a	n/a	-SEK 146m
Jun 30 2022	n/a	n/a	-SEK 147m
Mar 31 2022	n/a	n/a	-SEK 172m
Dec 31 2021	SEK 4m	SEK 2m	-SEK 183m
Sep 30 2021	n/a	n/a	-SEK 213m
Jun 30 2021	n/a	n/a	-SEK 219m
Mar 31 2021	n/a	n/a	-SEK 215m
Dec 31 2020	SEK 3m	SEK 1m	-SEK 218m
Sep 30 2020	n/a	n/a	-SEK 222m
Jun 30 2020	n/a	n/a	-SEK 210m
Mar 31 2020	n/a	n/a	-SEK 204m
Dec 31 2019	SEK 2m	SEK 1m	-SEK 188m
Sep 30 2019	n/a	n/a	-SEK 154m
Jun 30 2019	n/a	n/a	-SEK 56m
Mar 31 2019	n/a	n/a	-SEK 40m
Dec 31 2018	SEK 1m	SEK 1m	-SEK 13m
Sep 30 2018	n/a	n/a	SEK 30k
Jun 30 2018	n/a	n/a	-SEK 69m
Mar 31 2018	n/a	n/a	-SEK 45m
Dec 31 2017	SEK 1m	SEK 919k	-SEK 45m

보상 대 시장: Martin 의 총 보상 ($USD 321.95K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 257.75K ).

보상과 수익: Martin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Martin Amark (44 yo)

9.5yrs

테뉴어

SEK 3,360,000

보상

Mr. Martin Amark serves as Chief Executive Officer of Xbrane Biopharma AB (publ) and served as its Head of Investor Relation since February 14, 2019. He has experience from Bain & Co as a Management Consul...

리더십 팀

이름	위치	테뉴어	보상	소유권
Martin Amark	Chief Executive Officer	9.5yrs	SEK 3.36m	0.012% SEK 47.9k
Siavash Bashiri	COO, Head of Biosimilars & Deputy CEO	9.5yrs	SEK 1.79m	0.0076% SEK 29.5k
Jan-Willem De Gier	Co-Founder	no data	데이터 없음	데이터 없음
Samuel Wagner	Co-Founder & Member of Scientific Advisory Board	16.5yrs	데이터 없음	데이터 없음
Anette Lindqvist	CFO & Head of Investor Relations	3.5yrs	데이터 없음	0.00098% SEK 3.8k
David Vikström	Chief Technology Officer	10.5yrs	데이터 없음	0.0022% SEK 8.4k
Dina Jurman	Head of Clinical Affairs	6.8yrs	데이터 없음	0.000030% SEK 116.1
Anders Wallström	Head of Manufacturing & Supply Chain	5.5yrs	데이터 없음	0.00091% SEK 3.5k
Håkan Yildirim	Head of Intellectual Property	no data	데이터 없음	데이터 없음

9.5yrs

평균 재임 기간

45.5yo

평균 연령

경험이 풍부한 관리: XBRANE 의 관리팀은 노련하고 경험 (평균 재직 기간 9.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Samuel Wagner	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Björn Nilsson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mats Thoren	Independent Director	4.2yrs	SEK 435.00k	0.00026% SEK 1.0k
Peter Edman	Independent Director	9.5yrs	SEK 360.00k	0.00098% SEK 3.8k
Eva Nilsagard	Independent Director	5.2yrs	SEK 460.00k	0.00026% SEK 1.0k
Gunnar Von Heijne	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Joen Luirink	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Drew	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ivan Cohen-Tanugi	Independent Director	5.2yrs	SEK 360.00k	데이터 없음
Karin Wingstrand	Independent Director	9.5yrs	SEK 360.00k	0.0017% SEK 6.5k
Kirsti Gjellan	Independent Director	2.2yrs	SEK 385.00k	0.00016% SEK 619.1
Anders Tullgren	Independent Chairman of the Board	6.3yrs	SEK 820.00k	0.0046% SEK 17.8k

5.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: XBRANE 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

Xbrane Biopharma 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Recent updates

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

First quarter 2024 earnings: Revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Consensus EPS estimates fall by 35%

New minor risk - Financial position

New major risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Market cap size

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) Focuses on Development Portfolio and Introduces A Cost-Savings Scheme

Xbrane Biopharma AB (publ) to Report First Half, 2024 Results on Jul 17, 2024

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

New major risk - Financial position

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Feb 29, 2024

CFO & Head of Investor Relations recently bought kr236k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 15%

Now 22% undervalued

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 04, 2023

Insider recently bought kr156k worth of stock

Chief Executive Officer recently bought kr175k worth of stock

Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing

Forecast breakeven date pushed back to 2024

Price target increased to kr173

STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report First Half, 2023 Results on Aug 31, 2023

STADA Arzneimittel AG and Xbrane Biopharma AB (publ) Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci

Xbrane Biopharma AB (publ), Annual General Meeting, May 04, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 31, 2023

Xbrane Biopharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 31, 2023

Xbrane Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Chief Executive Officer recently sold kr1.0m worth of stock

An unknown buyer acquired an unknown minority stake in Xbrane Biopharma AB (publ) (OM:XBRANE) from Martin Amark and Siavash Bashiri.

Head of Regulatory Affairs recently bought kr104k worth of stock

Chief Technology Officer recently bought kr699k worth of stock

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Xbrane Biopharma AB (publ) Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Price target increased to kr235

Chief Executive Officer recently sold kr496k worth of stock

Xbrane Biopharma AB (Publ) Announces Positive Top-Line Results from the Pivotal Phase III Equivalence Trial for Xlucane™ - A Biosimilar Candidate to Lucentis

Xbrane Biopharma AB (publ)(OM:XBRANE) dropped from OMX Nordic Small Cap Index

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Consensus EPS estimates increase to -kr9.83

Forecast to breakeven in 2023

Head of Regulatory Affairs recently bought kr125k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr368k worth of stock

Chief Executive Officer recently sold kr172k worth of stock

Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB (publ) Appoints Erik Domines as General Counsel

Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings

New 90-day high: kr108

Xbrane Biopharma AB (publ) to Report Fiscal Year 2021 Results on Feb 16, 2022

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price